Ahem – number of units? [Dissolution / BCS / IVIVC]

posted by ElMaestro  – Belgium?, 2019-10-06 20:45 (389 d 08:06 ago) – Posting: # 20671
Views: 2,105

Hi Hötzi,


» Sure. The problem is the ‘regulatory crep’ I suspected in my post. Jiři showed nice simulations about the false positive rate. To squeeze the lower CL ≥50 is not another league but another sport. How many units will we have to test in the future? 24, 48, 96?

Am thinking loud here: You can bootstrap a principal answer to such questions as well.
You generate a dissolution dataset with n chambers for T and R; then you resample with replacement to generate datasets with m chambers (m > n, presumably) per product, to find out at which level of m you get an f2 limit >50.

This is quite simple, actually, to do the programming and simulation. But yes, if you end up with 326 chambers per product then I guess you are royally screwed.

We could do a publication about this. We'd need a candidate dataset, I don't think I have one for this which I could put into the public domain.

Could this even be done as a two-stage approach? You first look at bootstrap f2 levels in the initial n-chamber scenario. If you are passing, stop. Else, find your sample size m and run the (m-n) chambers on top, then re-bootstrap the whole thing. This would be a "two-treatment, m-chamber, tripple bootstrap, two-stage dissolution trial", and you may need to work with increased coverage intervals for alpha preservation.

Man, I should win a Nobel prize for this idea.:-D

I could be wrong, but...

Best regards,
ElMaestro

No, of course you do not need to audit your CRO if it was inspected in 1968 by the agency of Crabongostan.

Complete thread:

Activity
 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).
Forum time: Friday 04:52 UTC (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5